GERD drug Esomeprazole linked with Hyperprolactinaemia, reveals IPC Drug Safety alert

Published On 2023-10-06 08:50 GMT   |   Update On 2023-10-06 08:50 GMT

The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of September, has revealed that Esomeprazole, indicated for the treatment of Gastroesophageal reflux disease (GERD), is linked with adverse drug reactions (ADRs) named Hyperprolactinaemia.In connection to the above, the Indian Pharmacopoeia Commission (IPC) has cautioned healthcare...

Login or Register to read the full article

The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of September, has revealed that Esomeprazole, indicated for the treatment of Gastroesophageal reflux disease (GERD), is linked with adverse drug reactions (ADRs) named Hyperprolactinaemia.

In connection to the above, the Indian Pharmacopoeia Commission (IPC) has cautioned healthcare professionals to diligently monitor the potential occurrence of Adverse Drug Reactions (ADRs) when administering Esomeprazole.

For more details, check out the link given below:

Drug Safety Alert: Indian Pharmacopoeia Commission Flags ADR Linked To GERD Drug Esomeprazole



Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News